Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is a research study for patients that have an advanced cancer that is confined mostly to
the abdominal cavity and have failed treatment with conventional therapy, or for which no
standard treatment exists. The purpose of this study is to determine the dose of a
chemotherapy drug (called irinotecan) that can be administered safely into the abdominal
cavity. We also wish to identify the side effects of irinotecan when it is administered
directly into the abdomen. In this study, we will also determine the levels of irinotecan in
the blood and in the abdominal cavity.
Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It
is approved by the FDA for the treatment of colon cancer. It appears that some other
chemotherapy drugs are more effective and may have less side effects when they are
administered directly into the abdomen.